Clinical Trial Update: 68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer

View source ↗

Summary

This ClinicalTrials.gov entry describes a study evaluating 68Ga-FAPI PET/CT to assess axillary lymph node status after neoadjuvant therapy in clinically node-po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 68Ga-FAPI (gallium-68 labeled fibroblast activation protein inhibitor)

Snippet

Sponsor: Kunwei Shen | Conditions: BREAST CANCER, PET/CT | Status: RECRUITING